Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Healthcare providers ...
Demand for germline hereditary cancer genetic testing has increased because of reduced cost, gene discovery, expanding indications, and precision cancer therapies. The traditional model for germline ...
Medicare Part B covers various genetic tests for diagnosing genetic conditions, identifying cancer risks, and predicting medication responses if a doctor deems them medically necessary. The cost of ...
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease Women age 20-79 years diagnosed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results